Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome

Journal of Affective Disorders

Volumn 155, Issue 1, 2014, Pages 288-294

  Zhang, Chen ^a,b   Wu, Zhiguo ^a   Hong, Wu ^a   Wang, Zuowei ^a,c   Peng, Daihui ^a   Chen, Jun ^a   Yuan, Chengmei ^a   Yu, Shunying ^a   Xu, Lin ^b   Fang, Yiru ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c Mental Health Centre of Hongkou District   (China)

Author keywords

Association; B cell lymphoma 2; Major depressive disorder; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; MESSENGER RNA; PROTEIN BCL 2;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION;

ASSOCIATION; B-CELL/LYMPHOMA 2; MAJOR DEPRESSIVE DISORDER; TREATMENT-RESISTANT DEPRESSION;

ADULT; ALLELES; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; GENE FREQUENCY; GENES, BCL-2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS; TREATMENT OUTCOME;

EID: 84891890047     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.11.010     Document Type: Article

References (43)

1. H.S. Bachmann, F. Otterbach, R. Callies, H. Nuckel, M. Bau, K.W. Schmid, W. Siffert, and R. Kimmig The AA genotype of the regulatory BCL2 promoter polymorphism (-938C>A) is associated with a favorable outcome in lymph node-negative invasive breast cancer patients Clin. Cancer Res. 13 2007 5790 5797
2. J.C. Barrett, B. Fry, J. Maller, and M.J. Daly Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 2005 263 265
3. M. Bauer, L. Dell'Osso, S. Kasper, W. Pitchot, E.D. Vansvik, J. Kohler, L. Jorgensen, and S.A. Montgomery Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder J. Affect. Disord. 151 2013 209 219
4. M. Boldrini, A.N. Santiago, R. Hen, A.J. Dwork, G.B. Rosoklija, H. Tamir, V. Arango, and J. John Mann Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression Neuropsychopharmacology 38 2013 1068 1077
5. J. Cai, W. Zhang, Z. Yi, W. Lu, Z. Wu, J. Chen, S. Yu, Y. Fang, and C. Zhang Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms Psychopharmacology (Berlin) 230 2013 49 55
6. N.J. Camp, M.R. Lowry, R.L. Richards, A.M. Plenk, C. Carter, C.H. Hensel, V. Abkevich, M.H. Skolnick, D. Shattuck, K.G. Rowe, D.C. Hughes, and L.A. Cannon-Albright Genome-wide linkage analyses of extended Utah pedigrees identifies loci that influence recurrent, early-onset major depression and anxiety disorders Am. J. Med. Genet. B 135B 2005 85 93
7. K.X. Chen, Z.B. Hu, L.E. Wang, E.M. Sturgis, A.K. El-Naggar, W. Zhang, and Q.Y. Wei Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck Carcinogenesis 28 2007 2008 2012
8. S.H. Chiou, S.J. Chen, C.H. Peng, Y.L. Chang, H.H. Ku, W.M. Hsu, L.L.T. Ho, and C.H. Lee Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell Biochem. Biophys. Res. Commun. 343 2006 391 400
9. S.H. Chiou, H.H. Ku, T.H. Tsai, H.L. Lin, L.H. Chen, C.S. Chien, L.L.T. Ho, C.H. Lee, and Y.L. Chang Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway Br. J. Pharmacol. 148 2006 587 598
10. J.A. Cobb, J. Simpson, G.J. Mahajan, J.C. Overholser, G.J. Jurjus, L. Dieter, N. Herbst, W. May, G. Rajkowska, and C.A. Stockmeier Hippocampal volume and total cell numbers in major depressive disorder J. Psychiatr. Res. 47 2013 299 306
11. S. Cohen-Woods, I.W. Craig, and P. McGuffin The current state of play on the molecular genetics of depression Psychol. Med. 43 2013 673 687
12. A. Djordjevic, J. Djordjevic, I. Elakovic, M. Adzic, G. Matic, and M.B. Radojcic Fluoxetine affects hippocampal plasticity, apoptosis and depressive-like behavior of chronically isolated rats Prog. Neuropsychopharmacol. Biol. Psychiatry 36 2012 92 100
13. W.C. Drevets, J.L. Price, and M.L. Furey Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression Brain Struct. Funct. 213 2008 93 118
14. E. Eilat, S. Mendlovic, A. Doron, V. Zakuth, and Z. Spirer Increased apoptosis in patients with major depression: a preliminary study J. Immunol. 163 1999 533 534
15. Y. Fang, C. Yuan, Y. Xu, J. Chen, Z. Wu, L. Cao, Z. Yi, W. Hong, Y. Wang, K. Jiang, X. Cui, J.R. Calabrese, and K. Gao A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression J. Clin. Psychopharmacol. 31 2011 638 642
16. Y. Fang, C. Yuan, Y. Xu, J. Chen, Z. Wu, L. Cao, Z. Yi, W. Hong, Y. Wang, K. Jiang, K. Gao, X. Cui, and A.A. Nierenberg Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population J. Clin. Psychopharmacol. 30 2010 357 364
17. M. Fava Diagnosis and definition of treatment-resistant depression Biol. Psychiatry 53 2003 649 659
18. L.S. Gudmundsson, A.I. Scher, S. Sigurdsson, M.I. Geerlings, J.S. Vidal, G. Eiriksdottir, M.I. Garcia, T.B. Harris, O. Kjartansson, T. Aspelund, M.A. van Buchem, V. Gudnason, and L.J. Launer Migraine, depression, and brain volume: the AGES-Reykjavik study Neurology 80 2013 2138 2144
19. J. He, H. Luo, B. Yan, Y. Yu, H. Wang, Z. Wei, Y. Zhang, H. Xu, A. Tempier, X. Li, and X.M. Li Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease Neurobiol. Aging 30 2009 1205 1216
20. W. Hong, Y. Hu, Z. Li, Z. Yi, J. Chen, Z. Wu, J. Huang, L. Cao, S. Yu, X. Liu, D. Peng, K. Jiang, and Y. Fang The study on the effects of antidepressants treatment on the mRNA expression of B-cell lymphoma Leukemia-2 in peripheral leucodyte from patients with treatment-resistant depression Chin. J. Nerv. Ment. Dis. 38 2012 656 661
21. T.R. Insel, and E.M. Scolnick Cure therapeutics and strategic prevention: raising the bar for mental health research Mol. Psychiatry 11 2006 11 17
22. A.H. Kemp, E. Gordon, A.J. Rush, and L.M. Williams Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures CNS Spectr. 13 2008 1066 1086
23. G.F. Lehnerdt, P. Franz, A. Bankfalvi, S. Grehl, A. Kelava, H. Nuckel, S. Lang, K.W. Schmid, W. Siffert, and H.S. Bachmann The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma Ann. Oncol. 20 2009 1094 1099
24. M.E. Liu, C.C. Huang, A.C. Yang, P.C. Tu, H.L. Yeh, C.J. Hong, J.F. Chen, Y.J. Liou, C.P. Lin, and S.J. Tsai Effect of Bcl-2 rs956572 polymorphism on age-related gray matter volume changes PLoS One 8 2013 e56663
25. P.J. Lucassen, E. Fuchs, and B. Czeh Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex Biol. Psychiatry 55 2004 789 796
26. S.H. Maeng, J.G. Hunsberger, B. Pearson, P.X. Yuan, Y. Wang, Y.L. Wei, J. McCammon, R.J. Schloesser, R.L. Zhou, J. Du, G. Chen, B. McEwen, J.C. Reed, and H.K. Manji BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments Proc. Nat. Acad. Sci. U.S.A. 105 2008 8766 8771
27. K. Masago, Y. Togashi, S. Fujita, H. Nagai, Y. Sakamori, C. Okuda, Y.H. Kim, and M. Mishima Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy Oncology 84 2013 214 218
28. E. Nahon, A. Israelson, S. Abu-Hamad, and S.B. Varda Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death FEBS Lett. 579 2005 5105 5110
29. H. Nuckel, U.H. Frey, M. Bau, L. Sellmann, J. Stanelle, J. Durig, K.H. Jockel, U. Duhrsen, and W. Siffert Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia Blood 109 2007 290 297
30. Y.H. Park, S.K. Sohn, J.G. Kim, M.H. Lee, H.S. Song, M.K. Kim, J.S. Jung, J.J. Lee, H.J. Kim, and D.H. Kim Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy Clin. Cancer Res. 15 2009 2107 2115
31. S. Porcelli, C. Fabbri, and A. Serretti Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy Eur. Neuropsychopharmacol. 22 2012 239 258
32. âD report Am. J. Psychiatry 163 2006 1905 1917
33. I.H. Salem, F. Kamoun, N. Louhichi, M. Trigui, C. Triki, and F. Fakhfakh Impact of single-nucleotide polymorphisms at the TP53-binding and responsive promoter region of BCL2 gene in modulating the phenotypic variability of LGMD2C patients Mol. Biol. Rep. 39 2012 7479 7486
34. D. Souery, and J. Mendlewicz Compliance and therapeutic issues in resistant depression Int. Clin. Psychopharmacol. 13 1998 S13 S18
35. Y. Tesfaigzi, K. Rudolph, M.J. Fischer, and C.A. Conn Bcl-2 mediates sex-specific differences in recovery of mice from LPS-induced signs of sickness independent of IL-6 J. Appl. Physiol. 91 2001 2182 2189
36. I. Toda, B.D. Sullivan, L.A. Wickham, and D.A. Sullivan Gender- and androgen-related influence on the expression of proto-oncogene and apoptotic factor mRNAs in lacrimal glands of autoimmune and non-autoimmune mice J. Steroid Biochem. Mol. Biol. 71 1999 49 61
37. Y. Wang, X. Liu, D. Zhang, J. Chen, S. Liu, and M. Berk The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction BMC Med. 11 2013 32
38. Z. Wang, J. Fan, K. Gao, Z. Li, Z. Yi, L. Wang, J. Huang, C. Yuan, W. Hong, S. Yu, and Y. Fang Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder J. Mol. Neurosci. 50 2013 305 310
39. Z. Wang, Z. Li, J. Chen, J. Huang, C. Yuan, W. Hong, S. Yu, and Y. Fang Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population Genes Brain Behav. 11 2012 524 528
40. P. Xu, L. Liu, J.Z. Wang, K. Zhang, X.H. Hong, Q.F. Deng, J.J. Xiang, X.M. Zhang, M.A. He, T.C. Wu, and H. Guo Genetic variation in BCL2 3′-UTR was associated with lung cancer risk and prognosis in male Chinese population PLoS One 8 2013 e72197
41. C. Zhang, Z. Li, Z. Wu, J. Chen, Z. Wang, D. Peng, W. Hong, C. Yuan, S. Yu, Y. Xu, L. Xu, Z. Xiao, and Y. Fang A study of N-methyl-d-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression Psychopharmacology (Berlin) 2013 10.1007/s00213-013-3297-0
42. X. Zhang, C. Zhang, Z. Wu, Z. Wang, D. Peng, J. Chen, W. Hong, C. Yuan, Z. Li, S. Yu, and Y. Fang Association of genetic variation in CACNA1C with bipolar disorder in Han Chinese J. Affect. Disord. 150 2013 261 265
43. Y. Zhang, M. Chen, Z. Wu, J. Chen, S. Yu, Y. Fang, and C. Zhang Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results PLoS One 8 2013 e72652